Abstract | PURPOSE: PATIENTS AND METHODS: Patients with CUP who either had received previous chemotherapy or were previously untreated with poor-prognosis clinical features were eligible for this study. All patients received bevacizumab 10 mg/kg IV every 2 weeks, along with erlotinib 150 mg orally daily. Patients were re-evaluated after 8 weeks of treatment; those with objective response or stable disease continued treatment until disease progression. RESULTS: Forty-seven (92%) of 51 patients received at least 8 weeks of treatment. Five patients (10%) had partial responses, and 29 patients (61%) had stable disease as the best response. The median survival for the entire group was 7.4 months, with 33% of patients alive at 1 year. This regimen was well tolerated by most patients. CONCLUSION: The combination of bevacizumab and erlotinib has substantial activity in the treatment of patients with CUP. The median survival is superior to survival previously reported with second-line chemotherapy, and is similar to the results of many first-line chemotherapy trials in this setting. This regimen merits further evaluation in patients with CUP.
|
Authors | John D Hainsworth, David R Spigel, Cindy Farley, Dana S Thompson, Dianna L Shipley, F Anthony Greco, Minnie Pearl Cancer Research Network |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 25
Issue 13
Pg. 1747-52
(May 01 2007)
ISSN: 1527-7755 [Electronic] United States |
PMID | 17470864
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Quinazolines
- Vascular Endothelial Growth Factor A
- Bevacizumab
- Erlotinib Hydrochloride
- ErbB Receptors
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(adverse effects, therapeutic use)
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- ErbB Receptors
(antagonists & inhibitors)
- Erlotinib Hydrochloride
- Female
- Humans
- Male
- Middle Aged
- Neoplasms, Unknown Primary
(drug therapy)
- Quinazolines
(adverse effects, therapeutic use)
- Survival Analysis
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
|